Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF ACCRUED EXPENSES (Details)

v3.22.2.2
SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Accrued pre-clinical and clinical costs $ 1,405,142 $ 5,435,464
Accrued product development costs 34,262 203,676
Accrued compensation 1,707,393 2,715,368
Accrued administrative costs 721,500 1,213,699
Accrued interest 965,542 525,105
Total $ 4,833,839 $ 10,093,312